Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease

Journal of Medical Genetics

Volumn 41, Issue 4, 2004, Pages 261-265

  Robson, K J H ^a,b   Lehmann, D J ^c   Wimhurst, V L C ^b   Livesey, K J ^b   Combrinck, M ^c   Merryweather Clarke, A T ^b   Warden, D R ^c   Smith, A D ^c  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; TRANSFERRIN;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENOTYPE; HEMOCHROMATOSIS; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; MOLECULAR INTERACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE;

EID: 1942469548     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2003.015552     Document Type: Article

References (82)

1. Connor JR, Menzies SL, St Martin SM, Mufson EJ. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res 1992;31(1):75-83.
2. Loeffler DA, Connor JR, Juneau PL, Snyder BS, Kanaley L, DeMaggio AJ, Nguyen H, Brickman CM, LeWitt PA. Transferrin and iran in normal, Alzheimer's disease, and Parkinson's disease brain regions. J Neurochem 1995;65(2):710-24.
3. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A 1997;94(18):9866-8.
4. Thompson KJ, Shoham S, Connor JR. Iron and neurodegenerative disorders. Brain Res Bull 2001;55(2):155-64.
5. Ke Y, Qian ZM. Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol 2003;2:246-53.
6. Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000;71(2):621S-9S.
7. Perry G, Nunomura A, Hirai K, Zhu X, Perez M, Avila J, Castellani RJ, Atwood CS, Aliev G, Sayre LM, Takeda A, Smith MA. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? Free Radic Biol Med 2002;33(11):1475-9.
8. Praticò D. Alzheimer's disease and oxygen radicals: new insights. Biochem Pharmacol 2002;63(4):563-7.
9. Perry G, Taddea MA, Petersen RB, Castellani RJ, Harris PL, Siedlak SL, Cash AD, Liu Q, Nunomura A, Atwood CS, Smith MA. Adventitiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. Biometals 2003;16(1):77-81.
10. Feder JN, Penny DN, Irrinki A, Lee VK, Lebrón JA, Watson N, Tsuchihashi Z, Sigal E, Bjorkman PJ, Schatzman RC. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci U S A 1998;95:1472-7.
11. van Rensburg SJ, Carstens ME, Potocnik FC, Aucamp AK, Taljaard JJ. Increased frequency of the transferrin C2 subtype in Alzheimer's disease. Neuroreport 1993;4(11):1269-71.
12. Namekata K, Imagawa M, Terashi A, Ohta S, Oyama F, Ihara Y. Association of transferrin C2 allele with late-onset Alzheimer's disease. Hum Genet 1997;101(2):126-9.
13. Van Landeghem GF, Sikström C, Beckman LE, Adolfsson R, Beckman L. Transferrin C2, metal binding and Alzheimer's disease. Neuroreport 1998;9(2):177-9.
14. Hussain RI, Ballard CG, Edwardson JA, Morris CM. Transferrin gene polymorphism in Alzheimer's disease and dementia with Lewy bodies in humans. Neurosci Lett 2002;317(1):13-6.
15. Lleà A, Blesa R, Angelopoulos C, Pastor-Rubio P, Villa M, Oliva R, Bufill E. Transferrin C2 allele, haemochromatosis gene mutations, and risk for Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002;72(6):820-1.
16. Moalem S, Percy ME, Andrews DF, Kruck TP, Wong S, Dalton AJ, Mehta P, Fedor B, Worren AC. Are hereditary hemochromatosis mutations involved in Alzheimer disease? Am J Med Genet 2000;93(1):58-66.
17. Sampietro M, Caputo L, Casatta A, Meregalli M, Pellagatti A, Tagliabue J, Annoni G, Vergani C. The hemochromatosis gene affects the age of onset of sporadic Alzheimer's disease. Neurobiol Aging 2001;22(4):563-8.
18. Candore G, Licastro F, Chiappelli M, Franceschi C, Lio D, Rita Balistreri C, Piazza G, Colonna-Romano G, Grimaldi LM, Caruso C. Association between the HFE mutations and unsuccessful ageing: a study in Alzheimer's disease patients from Northern Italy. Mech Ageing Dev 2003;124(4):525-8.
19. Combarros O, Garcia-Román M, Fontalba A, Fernández-Luna JL, Llorca J, Infante J, Berciano J. Interaction of the H63D mutation in the hemochromatosis gene with the apolipoprotein E epsilon 4 allele modulates age of onset of Alzheimer's disease. Demenf Geriatr Cogn Disord 2003;15(3):151-4.
20. Pulliam JF, Jennings CD, Kryscio RJ, Davis DG, Wilson D, Montine TJ, Schmitt FA, Markesbery WR. Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE. Am J Med Genet 2003;119B(1):48-53.
21. Lehmann DJ, Williams J, McBroom J, Smith AD. Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer's disease and to identify high-risk subgroups. Neuroscience 2001;108(4):541-54.
22. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56(3):303-8.
23. Saunders AM, Strittmatter WJ, Schmechel D, St George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BA, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, Hulette C, Crain B, Goldgaber D, Roses AD. Association of apolipoprotein E allele epsilon 4 with late-onset Familial and sporadic Alzheimer's disease. Neurology 1993;43(8):1467-72.
24. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-anarysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278(16):1349-56.
25. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996;14(1):55-61.
26. Roth M, Huppert FA, Tym E, Mountjoy CQ. CAMDEX: The Cambridge examination for mental disorders of the elderly. Cambridge: Cambridge University Press, 1988.
27. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41(4):479-86.
28. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34(7):939-44.
29. Namekata K, Oyama F, Imagawa M, Ihara Y. Human transferrin (Tf): a single mutation at codon 570 determines Tf C1 or Tf C2 variant. Hum Genet 1997;100(3-4):457-8.
30. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJH. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997;34:275-8.
31. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJH, Jouanolle AM, Mosser A, David V, Le Gall J-Y, Halsall DJ, Elsey TS, Kelly A, Cox TM, Clare M, Bomford A, Vandwalle JL, Rochette J, Borot N, Coppin H, Roth M-P, Ryan E, Crowe J, Totaro A, Gasparini P, Roetto A, Camaschella C, Darke C, Wallace DF, Saeb-Parsy K, Dooley JS, Worwood M, Walker AP. Polymorphism in intron 4 of HFE does not compromise haemochromatosis mutation results. Nat Genet 1999;23:271.
32. Wenham PR, Price WH, Blandell G. Apolipoprotein E genotyping by one-stage PCR. Lancet 1991;337(8750):1158-9.
33. Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat 1996;5:299-314.
34. Buss S, Muller-Thomsen T, Hock C, Alberici A, Binetti G, Nitsch RM, Gal A, Finckh U. No association between DCP1 genotype and late-onset Alzheimer disease. Am J Med Genet 2002;114(4):440-5.
35. Lehmann D, Johnston C, Cortina Borja M, Smith A. Age influences the synergy between butyrylcholinesterase K variant and apolipoprotein E e4 in late-onset Alzheimer's disease. In: Doctor B, Quinn D, Rotundo R, eds. Structure and function of cholinesferases and related proteins. New York: Plenum, 1998:159-66.
36. Dautry-Varsat A, Ciechanover A, Lodish HF. pH and the recycling of transferrin during receptor-mediated endocytosis. Proc Natl Acad Sci U S A 1983;80(8):2258-62.
37. Burt MJ, George PM, Upton JD, Collett JA, Frampton CM, Chapman TM, Walmsley TA, Chapman BA. The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut 1998;43(6):830-6.
38. Merryweather-Clarke AT, Worwood M, Parkinson L, Mattock C, Pointon JJ, Shearman JD, Robson KJH. The effect of HFE mutations on serum ferritin and transferrin saturation in the Jersey population. Br J Haematol 1998;101:369-73.
39. Phatak PD, Ryan DH, Cappuccio J, Oakes D, Braggins C, Provenzano K, Eberly S, Sham RL. Prevalence and penetrance of HFE mutations in 4865 unselected primary care patients. Blood Cells Mol Dis 2002;29(1):41-7.
40. Njajou OT, Houwing-Duistermaat JJ, Osborne RH, Vaessen N, Vergeer J, Heeringa J, Pols HA, Hofman A, van Duijn CM. A population-based study of the effect of the HFE C282Y and H63D mutations on iron metabolism. Eur J Hum Genet 2003;11(3):225-31.
41. Beckman L, Beckman G. Transferrin C2 as an enhancer of cyto-and genotoxic damage. Prog Clin Biol Res 1986;209B:221-4.
42. Wong CT, Saha N. Effects of transferrin genetic phenotypes on total iron-binding capacity. Acta Haematol 1986;75(4):215-8.
43. Morris CM, Kerwin JM, Edwardson JA. Non-haem iron histochemistry of the normal and Alzheimer's disease hippocampus. Neurodegeneration 1994;3(4):267-75.
44. Connor JR, Menzies SL. Cellular management of iron in the brain. J Neurol Sci 1995;134(suppl):33-44.
45. Connor JR, Snyder BS, Arosio P, Loeffler DA, LeWitt P. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J Neurochem 1995;65(2):717-24.
46. Kawamata T, Tooyama I, Yamada T, Walker DG, McGeer PL. Lactotransferrin immunocytochemistry in Alzheimer and normal human brain. Am J Pathol 1993;142(5):1574-85.
47. Schipper HM, Cisse S, Stopa EG. Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain. Ann Neurol 1995;37(6):758-68.
48. Smith MA, Wehr K, Harris PL, Siedlak SL, Connor JR, Perry G. Abnormal localization of iron regulatory protein in Alzheimer's disease. Brain Res 1998;788(1-2):232-6.
49. Fleming J, Joshi JG. Ferritin: isolation of aluminum-ferritin complex from brain. Proc Natl Acad Sci U S A 1987;84(22):7866-70.
50. Piñero DJ, Hu J, Connor JR. Alterations in the interaction between iron regulatory proteins and their iron responsive element in normal and Alzheimer's diseased brains. Cell Mol Biol (Noisy-le-grand) 2000;46(4):761-76.
51. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter L, McPhee J, Sarang SS, Utsuki T, Greig NH, Lahiri DK, Tanzi RE, Bush AI, Giordano T, Gullans SR. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 2002;277(47):45518-28.
52. Palmer AM, Burns MA. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease. Brain Res 1994;645(1-2):338-42.
53. Lovell MA, Ehmann WD, Butler SM, Markesbery WR. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 1995;45(8):1594-1601.
54. Sayre IM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 1997;68(5):2092-7.
55. Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA, Markesbery WR. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci U S A 1991;88(23):10540-3.
56. Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, Aksenoya M, Gabbita SP, Wu JF, Carney JM, Lovell M, Markesbery WR, Butterfield A. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 1995;65(5):2146-56.
57. Good PF, Werner P, Hsu A, Olanow CW, Perl DP. Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol 1996;149(1):21-8.
58. Lyras L, Cairns NJ, Jenner A, Jenner P, Halliwell B. An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. J Neurochem 1997;68(5):2061-9.
59. Nunomura A, Perry G, Hirai K, Aliev G, Takeda A, Chiba S, Smith MA. Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome. Ann N Y Acad Sci 1999;893:362-4.
60. Shan X, Tashiro H, Lin CL. The identification and characterization of oxidized RNAs in Alzheimer's disease. J Neurosci 2003;23(12):4913-21.
61. Gabbita SP, Lovell MA, Markesbery WR. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J Neurochem 1998;71(5):2034-40.
62. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994;36(5):747-51.
63. Hayn M, Kremser K, Singewald N, Cairns N, Nemethova M, Lubec B, Lubec G. Evidence against the involvement of reactive oxygen species in the pathogenesis of neuronol death in Down's syndrome and Alzheimer's disease. Life Sci 1996;59(7):537-44.
64. Montine KS, Kim PJ, Olson SJ, Markesbery WR, Montine TJ. 4-Hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease. J Neuropathol Exp Neurol 1997;56(8):866-71.
65. Cash AD, Perry G, Ogawa O, Raina AK, Zhu X, Smith MA. Is Alzheimer's disease a mitochondrial disorder? Neuroscientist 2002;8(5):489-96.
66. Hensley K, Camey JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd RA, Butterfield DA. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci U S A 1994;91(8):3270-4.
67. Kim HC, Yamada K, Nitta A, Olariu A, Tran MH, Mizuno M, Nakajima A, Nagai T, Kamei H, Jhoo WK, Im DH, Shin EJ, Hjelle OP, Ottersen OP, Park SC, Kato K, Mirault ME, Nabeshima T. Immunocytochemical evidence that amyloid beta (1-42) impairs endogenous antioxidant systems in vivo. Neuroscience 2003;119(2):399-419.
68. Braak H, Del Tredici K, Schultz C, Braak E. Vulnerability of select neuronal types to Alzheimer's disease. Ann N Y Acad Sci 2000;924:53-61.
69. LeVine SM, Macklin WB. Iron-enriched oligodendrocytes: a reexamination of their spatial distribution. J Neurosci Res 1990;26(4):508-12.
70. Connor JR, Menzies SL Relationship of iron to oligodendrocytes and myelination. Glia 1996;17(2):83-93.
71. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001;60(8):759-67.
72. Ramassamy C, Averill D, Beffert U, Theroux L, Lussier-Cacan S, Cohn JS, Christen Y, Schoofs A, Davignon J, Poirier J. Oxidative insults are associated with apolipoprotein E genotype in Alzheimer's disease brain. Neurobiol Dis 2000;7(1):23-37.
73. Shea TB, Rogers E, Ashline D, Ortiz D, Sheu MS. Apolipoprotein E deficiency promotes increased oxidative stress and compensatory increases in antioxidants in brain tissue. Free Radic Biol Med 2002;33(8):1115-20.
74. Montine KS, Olson SJ, Amamath V, Whetsell WO Jr, Graham DG, Montine TJ. Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. Am J Pathol 1997;150(2):437-43.
75. Ramassamy C, Averill D, Beffert U, Bastianetto S, Theroux L, Lussier-Cacan S, Cohn JS, Christen Y, Davignon J, Quirion R, Poirier J. Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radic Biol Med 1999;27(5-6):544-53.
76. Tamaoka A, Miyatake F, Matsuno S, Ishii K, Nagase S, Sahara N, Ono S, Mori H, Wakabayashi K, Tsuji S, Takahashi H, Shoji S. Apolipoprotein E allele-dependent antioxidant activity in brains with Alzheimer's disease. Neurology 2000;54(12):2319-21.
77. Lehmann DJ, Wiebusch H, Marshall SE, Johnston C, Warden DR, Morgan K, Schappert K, Poirier J, Xuereb J, Kalsheker N, Welsh KI, Smith AD. HLA class I, II and III genes in confirmed late-onset Alzheimer's disease. Neurobiol Aging 2001;22(1):71-7.
78. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo Jr R, Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ, Drayna DT, Risch NJ, Bacon BR, Wolff RK. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
79. Ruddy DA, Kronmal GS, Lee VK, Mintier GA, Quintana L, Domingo Jr R, Meyer NC, Irrinki A, McClelland EE, Fullan A, Mapa FA, Moore T, Thomas W, Loeb DB, Harmon C, Tsuchihashi Z, Wolff RK, Schatzman RC, Feder JN. A 1.1-Mb transcript map of the hereditary hemochromatosis locus. Genome Res 1997;7:441-56.
80. Merryweather-Clarke AT, Pointon JJ, Jouanolle AM, Rochette J, Robson KJH. Geography of HFE C282Y and H63D mutations. Genef Test 2000;4:183-98.
81. Growdon JH, Locascio JJ, Corkin S, Gomez-Isla T, Hyman BT. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology 1996;47(2):444-8.
82. Slooter AJ, Houwing-Duistermaat JJ, van Harskamp F, Cruts M, Van Broeckhoven C, Breteler MM, Hofman A, Stijnen T, van Duijn CM. Apolipoprotein E genotype and progression of Alzheimer's disease: the Rotterdam Study. J Neurol 1999;246(4):304-8.